JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) (USD $)	9 Months Ended	12 Months Ended	14 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Aug. 23, 2013
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures		$ 6,000,000
Joint Venture Investments In Voting Common Ownership Units (in shares)		600,000
Joint Venture Method Investment Ownership Percentage		60.00%
Joint Venture Investments In Non Voting Preferred Ownership Units		5,000,000
Payments to Acquire Long-term Investments		3,300,000
Joint Venture Investments Common Ownership Units, Coventure (in shares)		400,000
Ownership Percentage Coventure		40.00%
Percentage Of Royalty Payment		3.00%
Development Activities Monthly Fee		63,000
Accounting and Administrative Monthly Fee		1,000
Investments In and Advance To Affiliates Additional Performance Measured Incentive Fee		250,000
Joint Venture Losses Recognition Criteria, Common Ownership Equity		0
Joint Venture, Operating Expenses, Inter Company Transactions	2,253,000		3,436,000
Joint Venture, Operating Expenses Allocated To Company	2,059,000		2,769,000
Percentage Of Non Royalty Income		15.00%
Funds From Escrow				800,000
Exclusive License Agreement [Member]
Annual Maintenance Payments		25,000
Exclusive License Agreement [Member] | Maximum [Member]
Milestone Payments		1,000,000
Royalty Expense		5,000,000
Exclusive License Agreement [Member] | Minimum [Member]
Milestone Payments		50,000
Royalty Expense		1,000,000
Corporate Joint Venture [Member]
Investments In and Advance To Affiliates Additional Performance Measured Incentive Fee		2,700,000
Voting Common Ownership Units [Member]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures		1,000,000
Non Voting Preferred Ownership Units [Member]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures		$ 5,000,000